Jiangsu Hengrui Medicine (600276 CH) - Q3 Performance Improved with Promising Innovative Pipeline
This article analyzed Hengrui's Q3 performance, strengths in innovation, promotion and internationalization, as well as its forecast and rating.
527 Views
Jacobio Pharma: Focus on Novel Targets
An in-depth overview of the proposed listing of Jacobio Pharmaceuticals using a framework that touches on the science, market opportunity,...
497 Views
Betta Pharmaceuticals (300558.SZ) - The Harvest Season Is Coming
Icotinib hydrochloride ensures stable cash flow for Betta for years. Icotinib hydrochloride is a National Class 1.1 new drug that is independently...
541 Views
Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)
In our first insight, we covered the company's background, particularly its management team and its product pipeline.In this insight, we will...
2.3k Views
Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)
Zai Lab is looking to raise US$100m in the US listing. The company has a short history of three years and does not have a commercial product at the...
1.7k Views